[1]
|
Kelley, R.K., Bridgewater, J., Gores, G.J. and Zhu, A.X. (2020) Systemic Therapies for Intrahepatic Cholangiocarcinoma. Journal of Hepatology, 72, 353-363. https://doi.org/10.1016/j.jhep.2019.10.009
|
[2]
|
Esnaola, N.F., Meyer, J.E., Karachristos, A., et al. (2016) Evaluation and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. Cancer, 122, 1349-1369. https://doi.org/10.1002/cncr.29692
|
[3]
|
Lamarca, A., Edeline, J., McNamara, M.G., et al. (2020) Current Standards and Future Perspectives in Adjuvant Treatment for Biliary Tract Cancers. Cancer Treatment Reviews, 84, Article ID: 101936.
https://doi.org/10.1016/j.ctrv.2019.101936
|
[4]
|
Mosconi, C., Solaini, L., Vara, G., et al. (2021) Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma—A Systemic Review and Meta-Analysis. CardioVascular and Interventional Radiology, 44, 728-738. https://doi.org/10.1007/s00270-021-02800-w
|
[5]
|
Judith, W, Grace, C.-R., Megan, D., et al. (2023) Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study. JVIR, 30, 1185-1192.
https://doi.org/10.1016/j.jvir.2019.03.018
|
[6]
|
Yang, J., Wang, J., Zhou, H., et al. (2018) Efficacy and Safety of Endoscopic Radiofrequency Ablation for Unresectable Extrahepatic Cholangiocarcinoma: A Randomized Trial. Endoscopy, 50, 751-760.
https://doi.org/10.1055/s-0043-124870
|
[7]
|
Oh, D.Y., He, A.R., Qin, S., et al. (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 1, EVIDoa2200015. https://doi.org/10.1056/EVIDoa2200015
|
[8]
|
Yang, J., Zhu, F., Wang, H., Rong, L., Wu, P., Li, Z., et al. (2022) The Efficacy and Safety of Immune Checkpoint Inhibitor Based Combination Therapy in Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Cancer Manag Res, 14, 1399-1411.
|
[9]
|
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz Dit Busset, M. and Sapisochin, G. (2020) Liver Resection and Transplantation for Intrahepatic Cholangiocarcinoma. Journal of Hepatology, 72, 364-377.
https://doi.org/10.1016/j.jhep.2019.11.020
|
[10]
|
Chun, Y.S. and Javle, M. (2017) Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control, 24, 1-7. https://doi.org/10.1177/1073274817729241
|
[11]
|
Amin, M.B., Greene, F.L., Edge, S.B., et al. (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-Based to a More “Personalized” Approach to Cancer Staging. CA: A Cancer Journal for Clinicians, 67, 93-99. https://doi.org/10.3322/caac.21388
|
[12]
|
Wright, G.P., Perkins, S., Jones, H., et al. (2018) Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies. Annals of Surgical Oncology, 25, 83-90. https://doi.org/10.1245/s10434-017-6110-1
|
[13]
|
Primrose, J.N., Fox, R.P., Palmer, D.H., et al. (2019) Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study. The Lancet Oncology, 20, 663-673.
|
[14]
|
Kupietzky, A. and Ariche, A. (2022) Surgical Aspects of Intrahepatic Cholangiocarcinoma. Cancers, 14, Article No. 6265. https://doi.org/10.3390/cancers14246265
|
[15]
|
潘奇, 王鲁. 肝内胆管细胞癌手术难点和范围[J]. 中国实用外科杂志, 2016, 36(6): 706-708.
|
[16]
|
Farges, O., Fuks, D., Boleslawski, E., et al. (2011) Influence of Surgical Margins on Outcome in Patients with Intrahepatic Cholangiocarcinoma: A Multicenter Study by the AFC-IHCC-2009 Study Group. Annals of Surgery, 254, 824-830. https://doi.org/10.1097/SLA.0b013e318236c21d
|
[17]
|
Shimada, K., Sano, T., Nara, S., et al. (2009) Therapeutic Value of Lymph Node Dissection during Hepatectomy in Patients with Intrahepatic Cholangiocellular Carcinoma with Negative Lymph Node Involvement. Surgery, 145, 411-416. https://doi.org/10.1016/j.surg.2008.11.010
|
[18]
|
Eliza, W.B., Jordan, M.C., Timothy, M.P., et al. (2021) Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. Journal of Clinical Medicine, 10, Article No. 104. https://doi.org/10.3390/jcm10010104
|
[19]
|
Edeline, J., Benabdelghani, M., Bertaut, A., et al. (2019) Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. Journal of Clinical Oncology, 37, 658-667. https://doi.org/10.1200/JCO.18.00050
|
[20]
|
Hong, J.C., Jones, C.M., Duffy, J.P., et al. (2011) Comparative Analysis of Resection and Liver Transplantation for Intrahepatic and Hilar Cholangiocarcinoma: A 24-Year Experience in a Single Center. Archives of Surgery, 146, 683-689. https://doi.org/10.1001/archsurg.2011.116
|
[21]
|
Primrose, J.N., Fox, R.P., Palmer, D.H., et al. (2019) Capecitabine Compared with Observation in Resected Biliary Tract Cancer (BILCAP): A Randomised, Controlled, Multicentre, Phase 3 Study [Published Correction Appears in Lancet Oncol. 2019 Apr 2]. The Lancet Oncology, 20, 663-673.
|
[22]
|
Kim, T.W., Chang, H.M., Kang, H.J., et al. (2003) Phase II Study of Capecitabine plus Cisplatin as First-Line Chemotherapy in Advanced Biliary Cancer. Annals of Oncology, 14, 1115-1120. https://doi.org/10.1093/annonc/mdg281
|
[23]
|
Hong, Y.S., Lee, J., Lee, S.C., Hwang, I.G., Choi, S.H., Heo, J.S., Park, J.O., Park, Y.S., Lim, H.Y. and Kang, W.K. (2007) Phase II Study of Capecitabine and Cisplatin in Previously Untreated Advanced Biliary Tract Cancer. Cancer Chemotherapy and Pharmacology, 8, 321-328. https://doi.org/10.1007/s00280-006-0380-9
|
[24]
|
Valle, J., Wasan, H., Palmer, D.H., et al. (2010) Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. The New England Journal of Medicine, 362, 1273-1281. https://doi.org/10.1056/NEJMoa0908721
|
[25]
|
Shroff, R.T., Javle, M.M., Xiao, L., et al. (2019) Gemcitabine, Cisplatin, and Nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncology, 5, 824-830.
https://doi.org/10.1001/jamaoncol.2019.0270
|
[26]
|
Lamarca, A., Palmer, D.H., Wasan, H.S., et al. (2021) Second-Line FOLFOX Chemotherapy versus Active Symptom Control for Advanced Biliary Tract Cancer (ABC-06): A Phase 3, Open-Label, Randomised, Controlled Trial. The Lancet Oncology, 22, 690-701. https://doi.org/10.1016/S1470-2045(21)00027-9
|
[27]
|
Mason, M.C., Massarweh, N.N., Tzeng, C.D., et al. (2021) Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Annals of Surgical Oncology, 28, 6725-6735.
https://doi.org/10.1245/s10434-020-09536-w
|
[28]
|
Choi, W.J., Ivanics, T., Claasen, M., et al. (2022) Is It Safe to Administer Neoadjuvant Chemotherapy to Patients Undergoing Hepatectomy for Intrahepatic Cholangiocarcinoma? ACS-NSQIP Propensity-Matched Analysis. HPB (Oxford), 24, 1535-1542. https://doi.org/10.1016/j.hpb.2022.03.010
|
[29]
|
Buettner, S., Koerkamp, B.G., Ejaz, A., et al. (2017) The Effect of Preoperative Chemotherapy Treatment in Surgically Treated Intrahepatic Cholangiocarcinoma Patients—A Multi-Institutional Analysis. Journal of Surgical Oncology, 115, 312-318. https://doi.org/10.1002/jso.24524
|
[30]
|
Sutton, T.L., Billingsley, K.G., Walker, B.S., et al. (2021) Neoadjuvant Chemotherapy Is Associated with Improved Survival in Patients Undergoing Hepatic Resection for Intrahepatic Cholangiocarcinoma. The American Journal of Surgery, 221, 1182-1187. https://doi.org/10.1016/j.amjsurg.2021.02.029
|
[31]
|
Chen, J.S., Hsu, C., Chiang, N.J., et al. (2015) A KRAS Mutation Statusstratified Randomized Phase II Trial of Gemcitabine and Oxaliplatin Alone or in Combination with Cetuximab in Advanced Biliary Tract Cancer. Annals of Oncology, 26, 943-994. https://doi.org/10.1093/annonc/mdv035
|
[32]
|
Valle, J.W., Wasan, H., Lopes, A., et al. (2015) Cediranib or Placebo in Combination with Cisplatin and Gemcitabine Chemotherapy for Patients with Advanced Biliary Tract Cancer (ABC-03): A Randomised Phase 2 Trial. The Lancet Oncology, 16, 967-978. https://doi.org/10.1016/S1470-2045(15)00139-4
|
[33]
|
Demols, A., Borbath, I., Van Den Eynde, M., et al. (2020) Regorafenib after Failure of Gemcitabine and Platinum-Based Chemotherapy for Locally Advanced/Metastatic Biliary Tumors: REACHIN, a Randomized, Double-Blind, Phase II Trial. Annals of Oncology, 31, 1169-1177. https://doi.org/10.1016/j.annonc.2020.05.018
|
[34]
|
Lamarca, A., Edeline, J. and Goyal, L. (2022) How I Treat Biliary Tract Cancer. ESMO Open, 7, Article ID: 100378.
https://doi.org/10.1016/j.esmoop.2021.100378
|
[35]
|
Jaidee, R., Kukongviriyapan, V., Senggunprai, L., et al. (2022) Inhibition of FGFR2 Enhances Chemosensitivity to Gemcitabine in Cholangiocarcinoma through the AKT/MTOR and EMT Signaling Pathways. Life Sciences, 296, Article ID: 120427. https://doi.org/10.1016/j.lfs.2022.120427
|
[36]
|
Abou-Alfa, G.K., Sahai, V., Hollebecque, A., et al. (2020) Pemigatinib for Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma: A Multicentre, Open-Label, Phase 2 Study. The Lancet Oncology, 21, 671-684.
https://doi.org/10.1016/S1470-2045(20)30109-1
|
[37]
|
Goyal, L., Meric-Bernstam, F., Hollebecque, A., et al. (2023) Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. The New England Journal of Medicine, 388, 228-239. https://doi.org/10.1056/NEJMoa2206834
|
[38]
|
Abou-Alfa, G.K., Macarulla, T., Javle, M.M., et al. (2020) Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study [Published Correction Appears in Lancet Oncol. 2020 Oct; 21(10): E462]. The Lancet Oncology, 21, 796-807.
https://doi.org/10.1016/S1470-2045(20)30157-1
|
[39]
|
Lamberti, D., Cristinziano, G., Porru, M., et al. (2019) HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma [Published Correction Appears in Hepatology. 2019 Feb; 69(2): 925]. Hepatology, 69, 131-142. https://doi.org/10.1002/hep.30127
|
[40]
|
Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., et al. (2015) Genomic Spectra of Biliary Tract Cancer. Nature Genetics, 47, 1003-1010. https://doi.org/10.1038/ng.3375
|
[41]
|
Lu, J.C., Zeng, H.Y., Sun, Q.M., et al. (2019) Distinct PD-L1/PD-1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics, 9, 4678-4687.
https://doi.org/10.7150/thno.36276
|
[42]
|
Kim, R.D., Chung, V., Alese, O.B., et al. (2020) A Phase 2 Mul-ti-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract Cancer. JAMA Oncology, 6, 888-894. https://doi.org/10.1001/jamaoncol.2020.0930
|
[43]
|
Oh, D.Y., Chen, L.T., He, A.R., et al. (2019) A Phase III, Randomized, Double-Blind, Placebo-Controlled, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin for Patients with Advanced Biliary Tract Cancers: TOPAZ-1. Annals of Oncology, 30, V319. https://doi.org/10.1093/annonc/mdz247.157
|
[44]
|
Oh, D.Y., Lee, K.H., Lee, D.W., et al. (2022) Gemcitabine and Cisplatin plus Durvalumab with or without Tremelimumab in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open Label, Single Centre, Phase 2 Study. The Lancet Gastroenterology and Hepatology, 7, 522-532. https://doi.org/10.1016/S2468-1253(22)00043-7
|
[45]
|
Oh, D.-Y., et al. (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence, 1, 1-11. https://doi.org/10.1056/EVIDoa2200015
|
[46]
|
Shi, G.M., Huang, X.Y., Wu, D., et al. (2023) Toripalimab Com-bined with Lenvatinib and GEMOX Is Apromising Regimen as First-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma: A Single-Center, Single-Arm, Phase 2 Study. Signal Transduction and Targeted Therapy, 8, Ar-ticle No. 106. https://doi.org/10.1038/s41392-023-01317-7
|
[47]
|
Lin, Y., Peng, L., Dong, L., et al. (2022) Geospa-tial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 12, 2350-2371.
https://doi.org/10.1158/2159-8290.CD-21-1640
|
[48]
|
Wang, N., Huang, A., Kuang, B., et al. (2022) Progress in Radiotherapy for Cholangiocarcinoma. Frontiers in Oncology, 12, Article ID: 868034. https://doi.org/10.3389/fonc.2022.868034
|
[49]
|
Herrera, F.G., Bourhis, J. and Coukos, G. (2017) Radiotherapy Combination Opportunities Leveraging Immunity for the Next Oncology Practice. CA: A Cancer Journal for Clinicians, 67, 65-85. https://doi.org/10.3322/caac.21358
|
[50]
|
Chen, Y.X., Zeng, Z.C., Tang, Z.Y., et al. (2010) Determining the Role of External Beam Radiotherapy in Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 84 Patients. BMC Cancer, 10, Article No. 492.
https://doi.org/10.1186/1471-2407-10-492
|
[51]
|
Sandler, K.A., Veruttipong, D., Agopian, V.G., et al. (2016) Ste-reotactic Body Radiotherapy (SBRT) for Locally Advanced Extrahepatic and Intrahepatic Cholangiocarcinoma. Advances in Radiation Oncology, 1, 237-243.
https://doi.org/10.1016/j.adro.2016.10.008
|
[52]
|
Gkika, E., Hallauer, L., Kirste, S., et al. (2017) Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Intrahepatic and Extrahepatic Cholangiocarcinoma. BMC Cancer, 17, Article No. 781.
https://doi.org/10.1186/s12885-017-3788-1
|
[53]
|
Yu, Q., Liu, C., Pillai, A., et al. (2021) Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis. Liver Cancer, 10, 433-450.
https://doi.org/10.1159/000516880
|
[54]
|
Hong, T.S., Wo, J.Y., Yeap, B.Y., et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients with Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 34, 460-468. https://doi.org/10.1200/JCO.2015.64.2710
|
[55]
|
Sumiyoshi, T., Shima, Y., Okabayashi, T., et al. (2018) Chemoradio-Therapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World Journal of Surgery, 42, 2910-2918. https://doi.org/10.1007/s00268-018-4558-1
|
[56]
|
Chen, C., Liu, Y. and Cui, B. (2021) Effect of Radi-otherapy on T Cell and PD-1/PD-L1 Blocking Therapy in Tumor Microenvironment. Human Vaccines & Immunotherapeutics, 17, 1555-1567.
https://doi.org/10.1080/21645515.2020.1840254
|
[57]
|
Liu, X., Yao, J., Song, L., et al. (2019) Local and Abscopal Responses in Advanced Intrahepatic Cholangiocarcinoma with Low TMB, MSS, PMMR and Negative PD-L1 Expres-sion Following Combined Therapy of SBRT with PD-1 Blockade. The Journal for ImmunoTherapy of Cancer, 7, Arti-cle No. 204. https://doi.org/10.1186/s40425-019-0692-z
|
[58]
|
Liu, Z.L., Liu, X., Peng, H., et al. (2020) Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocar-Cinoma: A Case Report. Frontiers in Medicine (Lausanne), 7, Article No. 368.
https://doi.org/10.3389/fmed.2020.00368
|
[59]
|
Massani, M., Bonariol, L. and Stecca, T. (2021) Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholan-Giocarcinoma, a Comprehensive Review. Journal of Clinical Medicine, 10, Article No. 2552.
https://doi.org/10.3390/jcm10122552
|
[60]
|
Cercek, A., Boerner, T., Tan, B.R., et al. (2020) Assessment of Hepatic Arterial Infusion of Flouridine in Combination with Systemic Gemcitabine and Oxaliplatin in Patients with Un-Resectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology, 6, 60-67. https://doi.org/10.1001/jamaoncol.2019.3718
|
[61]
|
Zhou, T.Y., Zhou, G.H., Zhang, Y.L., et al. (2020) Drug-Eluting Beads Transarterial Chemoembolization with CalliSpheres Microspheres for Treatment of Unresectable Intrahepatic Cholan-Giocarcinoma. Journal of Cancer, 11, 4534-4541. https://doi.org/10.7150/jca.39410
|
[62]
|
Rayar, M., Sulpice, L., Edeline, J., et al. (2015) Intra-Arterial Yttrium-90 Radioembolization Combined with Systemic Chemotherapy Is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. Annals of Surgical Oncology, 22, 3102-3108. https://doi.org/10.1245/s10434-014-4365-3
|
[63]
|
Edeline, J., Touchefeu, Y., Guiu, B., et al. (2020) Radioembolization plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncology, 6, 51-59.
https://doi.org/10.1001/jamaoncol.2019.3702
|
[64]
|
Rustagi, T. and Jamidar, P.A. (2014) Intraductal Radiofrequency Ablation for Management of Malignant Biliary Obstruction. Digestive Diseases and Sciences, 59, 2635-2641. https://doi.org/10.1007/s10620-014-3237-9
|
[65]
|
Figueroa-Barojas, P., Bakhru, M.R., Habib, N.A., et al. (2013) Safety and Efficacy of Radiofrequency Ablation in the Management of Unresectable Bile Duct and Panereatie Cancer: A Novel Palliation Technique. Journal of Oncology, 2013, Article ID: 910897. https://doi.org/10.1155/2013/910897
|
[66]
|
Wu, L., Tsilimigras, D.I., Farooq, A., et al. (2019) Potential Survival Benefit of Radiofrequency Ablation for Small Solitary Intrahepatic Cholangiocarcinoma in Nonsurgically Managed Patients: A Population-Based Analysis. Journal of Surgical Oncology, 120, 1358-1364. https://doi.org/10.1002/jso.25736
|
[67]
|
Mizandari, M., Kumar, J., Pai, M., et al. (2018) Interventional Radiofre-quency Ablation: A Promising Therapeutic Modality in the Management of Malignant Biliary and Pancreatic Duct Ob-struction. Journal of Cancer, 9, 629-637.
https://doi.org/10.7150/jca.23280
|
[68]
|
Wu, T.T., Li, W.M., Li, H.C., et al. (2017) Percutaneous Intraductal Ra-diofrequency Ablation for Extrahepatic Distal Cholangiocarcinoma: A Method for Prolonging Stent Patency and Achieving Better Functional Status and Quality of Life. CardioVascular and Interventional Radiology, 40, 260-269. https://doi.org/10.1007/s00270-016-1483-2
|
[69]
|
Jin, Y., Zhao, Q., Fan, C., et al. (2023) Influence of Peripheral T-Cell Subsets of Radiofrequency Ablation of Tumors from Different Origins. Asian Journal of Surgery. https://doi.org/10.1016/j.asjsur.2023.12.089
|
[70]
|
Job, S., Rapoud, D., Dos Santos, A., et al. (2020) Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in In-tra-Hepatic Cholangiocarcinoma. Hepatology, 72, 965-981. https://doi.org/10.1002/hep.31092
|
[71]
|
Chaisaingmongkol, J., Budhu, A., Dang, H., et al. (2017) Common Mo-lecular Subtypes among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell, 32, 57-70.E3. https://doi.org/10.1016/j.ccell.2017.05.009
|
[72]
|
Sia, D., Hoshida, Y., Villanueva, A., et al. (2013) Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. Gastroen-terology, 144, 829-840.
https://doi.org/10.1053/j.gastro.2013.01.001
|
[73]
|
Chow, F.C. and Chok, K.S. (2019) Colorectal Liver Metastases: An Update on Multidisciplinary Approach. World Journal of Hepatology, 11, 150-172. https://doi.org/10.4254/wjh.v11.i2.150
|
[74]
|
Charriere, B., Muscari, F., Maulat, C., et al. (2017) Outcomes of Pa-tients with Hepatocellular Carcinoma Are Determined in Multidisciplinary Team Meetings. Journal of Surgical Oncology, 115, 330-336.
https://doi.org/10.1002/jso.24500
|